Pentostatin (Synonyms: CI 825, CL 67310465, DCF, 2′-Deoxycoformycin, Deoxycoformycin, NSC 218321, NSC 247520) |
| Katalog-Nr.GC12200 |
Pentostatin (2′-deoxycoformycin, Nipent) is an adenosine deaminase inhibitor with a Ki value of 1.2pM and an IC50 value of 1.4pM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 53910-25-1
Sample solution is provided at 25 µL, 10mM.
Pentostatin (2′-deoxycoformycin, Nipent) is an adenosine deaminase inhibitor with a Ki value of 1.2pM and an IC50 value of 1.4pM[1]. Pentostatin is used for hairy cell leukemia treatment, as well as another type of cancer[2]. The natural adenosine analog is produced by the bacterium Streptomyces antibioticus and the fungus Emericella nidulans[3].
In vitro, Pentostatin (100μM-1nM; 4h) inhibits the growth in soft agar of T cell colonies from PHA-stimulated human peripheral blood lymphocytes[4]. Pentostatin (1μM) also has the growth-inhibitory activity of 9-beta-D-arabinofuranosyladenine in human cultured cell lines derived from leukemias and lymphomas[5].
In vivo, Pentostatin (10μg; once; i.v) indirectly triggers Toll-like receptor 3 and enhances immune infiltration in tumors in a C57BL/6 nude mice model[6]. Pentostatin(0.16mg/kg; once per day; 7d; i.p) also shows cytotoxicity to T cells with a decrease in the number of Thy-1-positive cells in both spleen and lymph nodes in BALB/c (H-2d) mice[7]. The effect of Pentostatin(10-100μg/g; once; s.c) on the thymus was proven to be independent of the adrenal glands by the use of adrenalectomized mice[8].
References:
[1] Adamek, Rebecca N et al. “Identification of Adenosine Deaminase Inhibitors by Metal-binding Pharmacophore Screening.” *ChemMedChem*vol. 15,22 (2020): 2151-2156. doi:10.1002/cmdc.202000271
[2] “Pentostatin.” *LiverTox: Clinical and Research Information on Drug-Induced Liver Injury*, National Institute of Diabetes and Digestive and Kidney Diseases, 12 September 2020.
[3] Agarwal, R P et al. “Tight-binding inhibitors--IV. Inhibition of adenosine deaminases by various inhibitors.” *Biochemical pharmacology* vol. 26,5 (1977): 359-67. doi:10.1016/0006-2952(77)90192-7
[4] Colledge, N R et al. “Action of deoxycoformycin on human T cell colonies in vitro.” *Clinical and experimental immunology* vol. 50,1 (1982): 115-22.
[5] Kuroki, Y et al. “Potentiation of growth-inhibitory activity of 9-beta-D-arabinofuranosyladenine by 2'-deoxycoformycin in human cultured cell lines derived from leukemias and lymphomas.” *Japanese journal of cancer research : Gann* vol. 80,5 (1989): 482-9. doi:10.1111/j.1349-7006.1989.tb02340.x
[6] Tusup, Marina et al. “Epitranscriptomics modifier pentostatin indirectly triggers Toll-like receptor 3 and can enhance immune infiltration in tumors.” *Molecular therapy : the journal of the American Society of Gene Therapy* vol. 30,3 (2022): 1163-1170. doi:10.1016/j.ymthe.2021.09.022
[7] Tedde, A et al. “Animal model for immune dysfunction associated with adenosine deaminase deficiency.” *Proceedings of the National Academy of Sciences of the United States of America*vol. 77,8 (1980): 4899-903. doi:10.1073/pnas.77.8.4899
[8] Ratech, H et al. “Effects of deoxycoformycin in mice. III. A murine model reproducing multi-system pathology of human adenosine deaminase deficiency.” *The American journal of pathology* vol. 119,1 (1985): 65-72.
| Kinase experiment [1]: | |
Preparation Method | Fresh dilutions of Pentostatin (0.005, 0.05, 0.125, 0.5, 5, 12.5, 50, 125, 500, 1000μM) in phosphate buffer were prepared. 30μL of 13.8mUmL−1 adenosine deaminase (ADA) and 20μL of Pentostatin were added to successive wells in a row and thoroughly mixed. In the final two wells of the row, phosphate buffer and EHNA were added, respectively, in place of Pentostatin. Two more rows were prepared in the same manner and a fourth row was prepared with phosphate buffer in place of ADA. |
Reaction Conditions | After two minutes of incubation, isothiazolo adenosine (tzA) (50μL of 7.8μM) was added and mixed thoroughly. Wells were then excited at 322nm and emission monitored at 410nm. Intensity of emission was measured every 37 seconds for just over 30 minutes. |
Applications | The IC50 value of Pentostatin is 0.0014±0.0001μM, and Ki value is 0.0012±0.0002μM |
| Cell experiment [2]: | |
Cell lines | human Primary Lymphocytes |
Preparation Method | Freeze dried Pentostatin was reconstituted with PBS, resterilized by filtration and added to cultures by pipetting on to the surface of the agar. Control cultures received the same volume of saline. Pilot experiments showed that Pentostatin was much less effective when incorporated into the agar underlay than when pipetted on to the surface. Application of Pentostatin to the agar surface had the further advantage that it could be done at any time after setting up the culture. It is however difficult to be precise about drug concentrations reaching cells by diffusion through soft agar. Cited concentrations are those pipetted on to the agar surface and are therefore all over-estimates by up to 10-fold of the concentrations surrounding the cells, since the volume of saline in which the Pentostatin was applied was one tenth that of the agar in each well. |
Reaction Conditions | 100μM-1nM; 4h |
Applications | T cells already proliferating in response to PHA are less sensitive to Pentostatin, implying that S-phase events are not primary targets of the drug's action. Colony inhibition does not appear to be due to alteration in the production of, or sensitivity to, soluble T cell growth factors. In suspension cultures, Pentostatin at concentrations up to 100μM fails to inhibit early PHA-induced volume changes, or later mitosis, in peripheral blood lymphocytes. |
| Animal experiment [3]: | |
Animal models | C57BL/6 nude mice |
Preparation Method | Mice were implanted subcutaneously with CT26/NY-ESO-1 cells and received 10μg of intravenous Pentostatin alone (“Pentostatin”) or together with 1mg intraperitoneally of an anti-IFNAR antibody (“Pentostatin + anti-IFNAR ab”) 6 days later. As controls, tumor-bearing mice received only the anti-IFNAR ab (“anti-IFNAR ab”) or were left untreated (“Untreated”) at day 6. |
Dosage form | 10μg; once; i.v |
Applications | Pentostatin can be used to treat CT26/NY-ESO-1 tumors, but its activity is abrogated by anti-IFNAR ab |
References: | |
| Cas No. | 53910-25-1 | SDF | |
| Überlieferungen | CI 825, CL 67310465, DCF, 2′-Deoxycoformycin, Deoxycoformycin, NSC 218321, NSC 247520 | ||
| Chemical Name | (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol | ||
| Canonical SMILES | C1C(C(OC1N2C=NC3=C2NC=NCC3O)CO)O | ||
| Formula | C11H16N4O4 | M.Wt | 268.27 |
| Löslichkeit | ≥ 13.4 mg/mL in DMSO, ≥ 26.8 mg/mL in Water | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7276 mL | 18.6379 mL | 37.2759 mL |
| 5 mM | 0.7455 mL | 3.7276 mL | 7.4552 mL |
| 10 mM | 0.3728 mL | 1.8638 mL | 3.7276 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *